Location Directory

Clinical trials in Detroit, Michigan

This page shows live ClinicalTrials.gov search results for Detroit, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:56 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7238

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: FDC fianlimab+cemiplimab, Cemiplimab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 14 more

Conditions: Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Secondary Acute Myeloid Leukemia
Interventions: Azacitidine, Gemtuzumab Ozogamicin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 177
States / cities: Burbank, California • Palo Alto, California • Sacramento, California + 122 more

Conditions: Hepatocellular Carcinoma
Interventions: TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab; Drug
Lead sponsor: Tvardi Therapeutics, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 21
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more

Conditions: Glioblastoma
Interventions: INO-5401, INO-9012, Cemiplimab, Radiation Therapy, Temozolomide; Biological · Radiation · Drug
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 21
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 15 more

Conditions: Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions: Biopsy Procedure, Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 479
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 303 more

Conditions: Metastatic Prostate Cancer
Interventions: AZD0516, AZD9574; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Fayetteville, Arkansas • Los Angeles, California • Towson, Maryland + 8 more

Conditions: Breast Cancer; HER2-positive; Metastatic
Interventions: Trastuzumab deruxtecan, Placebo, Taxane, Pertuzumab, Trastuzumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 30
States / cities: Tucson, Arizona • Springdale, Arkansas • Glendale, California + 25 more

Conditions: Desmoplastic Melanoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Pembrolizumab, Positron Emission Tomography, Therapeutic Conventional Surgery; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 280
States / cities: Fairbanks, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 199 more

Conditions: Non-small Cell Lung Cancer
Interventions: BNT326, Pumitamig; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 11
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 8 more

Conditions: Atopic Dermatitis
Interventions: APG777; Drug
Lead sponsor: Apogee Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 23
States / cities: Fountain Valley, California • Los Angeles, California • Coral Gables, Florida + 20 more

Conditions: Triple Negative Breast Neoplasms
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 47
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more

Conditions: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Interventions: larotrectinib(Vitrakvi, BAY2757556); Drug
Lead sponsor: Bayer; Industry
Eligibility: Not listed
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 33
States / cities: Los Angeles, California • Newport Beach, California • Palo Alto, California + 28 more

Clinical trials in Detroit, Michigan

Filter and sort this location

Live official records

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body